What's Happening?
Tune Therapeutics has presented positive Phase 1b/2a proof of concept data for TUNE-401, an epigenetic silencer for hepatitis B, at the European Association for the Study of Liver (EASL) Congress. The study demonstrated deep and durable antiviral activity,
including direct silencing of cccDNA, a key barrier to curing chronic hepatitis B (CHB). TUNE-401, delivered intravenously, showed dose-dependent repression of HBV biomarkers and was well-tolerated in patients. The trial included single and multiple-dose cohorts, with biomarker repression observed in 100% of participants at higher dose levels. The study's findings suggest a potential pathway to a finite cure for HBV patients.
Why It's Important?
The development of TUNE-401 marks a significant step forward in the treatment of chronic hepatitis B, a condition affecting over 240 million people globally. Current therapies rarely achieve a functional cure due to the persistence of cccDNA. TUNE-401's ability to directly silence this viral reservoir could lead to a breakthrough in achieving a finite cure for HBV. This advancement could improve long-term health outcomes for millions of patients and represents a major milestone in the field of epigenetic therapies.
What's Next?
Tune Therapeutics plans to advance TUNE-401 into a larger Phase 2 study, focusing on dose optimization and expanded multi-dose cohorts. The initiation of Phase 2 is expected by late 2026. The company aims to deliver the first epigenetic backbone therapy for HBV infection, potentially transforming the treatment landscape for chronic hepatitis B. Continued research and development will focus on refining the therapy's efficacy and safety profile, with the goal of providing a new standard of care for HBV patients.
